Poster presentations related to multiple myeloma will take place during one session at the 2015 American Society of Clinical Oncology (ASCO) annual meeting. The session will take place Sunday, May 31.

The list below contains the titles and authors of all multiple myeloma poster presentations at ASCO 2015. Each entry in the list also includes a link to the full text of the relevant abstract at the ASCO website.

Links to PDF files containing posters will be added to entries in this list as those files are made available to The Beacon courtesy of the ASCO presenters.

The Beacon also has similar lists of ASCO 2015 multiple myeloma-related oral presentations, e-abstracts, and education session presentations as well as news articles about multiple myeloma at the ASCO 2015 meeting.

8523 - Updated analysis of CALGB/ECOG/BMT CTN 100104: Lenalidomide (Len) vs. placebo (PBO) maintenance therapy after single autologous stem cell transplant (ASCT) for multiple myeloma (MM)

Sarah A. Holstein, Kouros Owzar, Paul G. Richardson, Chen Jiang, Craig C. Hofmeister, Hani Hassoun, David Duane Hurd, Edward Allen Stadtmauer, Sergio Giralt, Steven M Devine, Vera Hars, John R. Postiglione, Daniel Jordan Weisdorf, Ravi Vij, Jan S Moreb, Natalie Scott Callander, Thomas G. Martin, Thomas C. Shea, Kenneth Carl Anderson, Philip L. McCarthy (abstract; poster [PDF] courtesy of Dr. Holstein)

8524 - Updated overall survival (OS) in stem cell transplant (SCT)-ineligible newly diagnosed multiple myeloma (NDMM) patients (pts) treated with continuous lenalidomide plus low-dose dexamethasone (Rd) vs melphalan, prednisone, and thalidomide (MPT)

Thierry Facon, Cyrille Hulin, Meletios A. Dimopoulos, Andrew Belch, Donna Ellen Reece, John V. Catalano, Antonio Pinto, Heinz Ludwig, Nizar J. Bahlis, Michele Cavo, Philippe Moreau, Lugui Qiu, Richard LeBlanc, Rik Schots, S. Vincent Rajkumar, Jennifer Marek, Guang Chen, Annette L. Ervin-Haynes (abstract)

8525 - Effect of carfilzomib, lenalidomide, and dexamethasone (KRd) vs lenalidomide and dexamethasone (Rd) in patients with relapsed multiple myeloma (RMM) by line of therapy: Secondary analysis from an interim analysis of the phase III study ASPIRE (NCT01080391)

Meletios A. Dimopoulos, A. Keith Stewart, S. Vincent Rajkumar, Tamás Masszi, Albert Oriol, Roman Hajek, Laura Rosinol, David Samuel DiCapua Siegel, Georgi Mihaylov, Vesselina Goranova-Marinova, Peter Rajnics, Aleksandr Suvorov, Ruben Niesvizky, Andrzej J. Jakubowiak, Jesus F. San Miguel, Heinz Ludwig, Naseem J. Zojwalla, Philippe Moreau, Antonio Palumbo (abstract)

8526 - Panobinostat plus bortezomib and dexamethasone in patients with relapsed or relapsed and refractory multiple myeloma who received prior bortezomib and IMiDs: A predefined subgroup analysis of PANORAMA 1

Jesus F. San Miguel, Vania T.M. Hungria, Sung-Soo Yoon, Meral Beksac, Meletios A. Dimopoulos, Ashraf Elghandour, Wieslaw W. Jedrzejczak, Andreas Guenther, Thanyaphong Na Nakorn, Noppadol Siritanaratkul, Robert L. Schlossman, Jian Hou, Philippe Moreau, Sagar Lonial, Jae Hoon Lee, Hermann Einsele, Monika Sopala, Bourras-Rezki Bengoudifa, Claudia Corrado, Paul G. Richardson (abstract)

8527 - Updated results from CHAMPION-1, a phase I/II study investigating weekly carfilzomib with dexamethasone for patients (Pts) with relapsed or refractory multiple myeloma (RRMM)

James R. Berenson, Alan Cartmell, Alberto Bessudo, Roger M. Lyons, Wael A. Harb, Dimitrios Tzachanis, Morton Coleman, Ralph V. Boccia, Robert M. Rifkin, Priti Patel, Sandra Dixon, Jesus G. Berdeja (abstract)

8528 - A phase II study of panobinostat with lenalidomide and weekly dexamethasone in myeloma

Ajai Chari, Hearn J. Cho, Samir S. Parekh, Amishi Dhadwal, Katarzyna Garcia, Gillian Morgan, Natalie Belostotsky, Crystle Carter, Donna Catamero, Juliet Escalon, Daniel Verina, Moon-Hee Yum, Lisa La, Elaine Chan, Jude Gullie, Sundar Jagannath (abstract; poster [PDF] courtesy of Dr. Chari)

8530 - Lenalidomide and low-dose dexamethasone (Ld) is equivalent to Ld plus autologous stem cell transplant (ASCT) in newly diagnosed multiple myeloma (NDMM): Results of a randomized, phase III trial

Suzanne Lentzsch, Susanna Miao, Jordan Mark Schecter, Kent A. Griffith, Daniel Paul Normolle, Markus Y Mapara, Robert L Redner, Nicolas Villanueva (abstract; poster [PDF] courtesy of Dr. Lentzsch)

8537 - Phase 1 first-in-human trial of oral CUDC-907, a dual inhibitor of PI3K and HDAC, in patients with refractory/relapsed lymphoma or multiple myeloma

Jesus G. Berdeja, Yasuhiro Oki, Manish R. Patel, Amanda Copeland, Ian Flinn, Sattva Swarup Neelapu, Jaye Viner, Jing Wang, John F. Gerecitano, Anas Younes (abstract; poster [PDF] courtesy of Dr. Berdeja)

8573 - A randomized phase II study of bortezomib (Btz)/dexamethasone (dex) with or without elotuzumab (Elo) in patients (pts) with relapsed/refractory multiple myeloma (RRMM)

Andrzej J. Jakubowiak, Massimo Offidani, Brigitte Pegourie, Javier De La Rubia, Laurent Garderet, Kamel Laribi, Alberto Bosi, Roberto Marasca, Jacob Laubach, Ann Mohrbacher, Angelo Michele Carella, Anil K. Singhal, Claire Tsao, Mark John Lynch, Eric W. Bleickardt, Ying-Ming Jou, Antonio Palumbo (abstract)

8574 - A phase I/IIa study of the human anti-CD38 antibody MOR202 (MOR03087) in relapsed or refractory multiple myeloma (rrMM)

Marc S. Raab, Hartmut Goldschmidt, Hermine Agis, Igor Blau, Hermann Einsele, Monika Martha Engelhardt, Barbara Ferstl, Martin Gramatzki, Christoph Röllig, Katja Weisel, Pia Kloepfer, Dominika Weinelt, Stefan Härtle, Christian Peschel (abstract; poster [PDF] courtesy of Dr. Raab)

8575 - Analysis of outcomes based on response for patients with relapsed or relapsed and refractory multiple myeloma in the phase 3 PANORAMA 1 study

Vania T.M. Hungria, Jesus F. San Miguel, Sung-Soo Yoon, Meral Beksac, Meletios A. Dimopoulos, Ashraf Elghandour, Wieslaw W. Jedrzejczak, Andreas Guenther, Thanyaphong Na Nakorn, Noppadol Siritanaratkul, Robert L. Schlossman, Jian Hou, Philippe Moreau, Sagar Lonial, Jae Hoon Lee, Hermann Einsele, Monika Sopala, Bourras-Rezki Bengoudifa, Claudia Corrado, Paul G. Richardson (abstract)

8576 - Phase I interim safety and efficacy of venetoclax (ABT-199/GDC-0199) monotherapy for relapsed/refractory (R/R) multiple myeloma (MM)

Shaji Kumar, Ravi Vij, Jonathan L. Kaufman, Joseph Mikhael, Thierry Facon, Philippe Moreau, Martine Amiot, Stefanie Alzate, Lura J Morris, Jeremy A Ross, Martin Dunbar, Ming Zhu, Suresh K Agarwal, Joel Leverson, Sari H. Enschede, Rod Humerickhouse, Cyrille Touzeau (abstract; poster [PDF] courtesy of Dr. Kumar)

8577 - The prognostic significance of CD45 expression by clonal bone marrow plasma cells in multiple myeloma

Wilson I. Gonsalves, Vincent Rajkumar, William Morice, Michael Timm, Angela Dispenzieri, Francis Buadi, Martha Lacy, Yi Lin, David Dingli, Suzanne R. Hayman, Steven R. Zeldenrust, Stephen J. Russell, Nelson Leung, Prashant Kapoor, Morie A. Gertz, Shaji Kumar (abstract)

8578 - Outcome at first relapse after frontline RVD regimen plus lenalidomide maintenance in transplant eligible MM patients

Murielle Roussel, Benjamin Hebraud, Denis Caillot, Xavier Leleu, Margaret Macro, Cyrille Hulin, Carine Chaleteix, Martine Escoffre Barbe, Lionel Karlin, Gerald Marit, Laurent Garderet, Brigitte Pegourie, Anne-Marie Stoppa, Pascal Lenain, Bruno Royer, Herve Avet-Loiseau, Michel Attal (abstract; poster [PDF] courtesy of Dr. Roussel)

8579 - Preliminary safety and efficacy of evofosfamide (TH-302), an investigational hypoxia-activated prodrug, combined with bortezomib and dexamethasone in patients with relapsed/refractory multiple myeloma (RR MM)

Jacob Laubach, Noopur S. Raje, Andrew Jenho Yee, Philippe Armand, Robert L. Schlossman, Jacalyn Rosenblatt, Jacquelyn Ann Hedlund, Michael Gary Martin, Craig H. Reynolds, Kenneth H. Shain, Ira Zackon, Laura Stampleman, Erica Boswell, Stacey Chuma, Rebecca Liguori, Damian Handisides, Stew Kroll, Kenneth Carl Anderson, Paul G. Richardson, Irene M. Ghobrial (abstract; poster [PDF] courtesy of Dr. Laubach)

8580 - Phase 1b interim results: Venetoclax (ABT-199/GDC-0199) in combination with bortezomib (BTZ) and dexamethasone (Dex) in relapsed/refractory (R/R) multiple myeloma (MM)

Cyrille Touzeau, Asher Alban Akmal Chanan-Khan, Andrew Warwick Roberts, Amit Agarwal, Thierry Facon, Daniel Lebovic, Philippe Moreau, David E Darden, Lura J Morris, Jeremy A Ross, Ahmed H. Salem, Wijith Munasinghe, Ming Zhu, Joel Leverson, Sari H. Enschede, Rod Humerickhouse, Simon J Harrison (abstract; poster [PDF] courtesy of Dr. Touzeau)

8581 - Total marrow irradiation (TMI) with helical tomotherapy and peripheral blood progenitor cell rescue (PBPC) following high-dose melphalan (Mel) and PBPC as part of tandem autologous transplant (TAT) for patients with multiple myeloma

George Somlo, An Liu, Timothy E. Schultheiss, Paul Henry Frankel, Ricardo Tomas Spielberger, Leslie Popplewell, Kenny Zhou, Donna Hawkins, Amrita Y. Krishnan, Firoozeh Sahebi, Pablo Miguel Parker, Stephen J. Forman, Jeffrey Y.C. Wong (abstract; poster [PDF] courtesy of Dr. Somlo)

8582 - Overall survival in newly diagnosed MM patients with del(17p): A report from the Connect MM Registry

Jatin J. Shah, Rafat Abonour, Brian G. Durie, Jayesh Mehta, Mohit Narang, Howard R. Terebelo, Cristina Gasparetto, Kathleen Toomey, James W. Hardin, Shankar Srinivasan, Gail Larkins, Rosanna J. Ricafort, Yasir M. Nagarwala, Robert M. Rifkin (abstract; poster [PDF] courtesy of Dr. Shah)

8583 - Outcomes of high, t(11;14), and standard cytogenetic risk multiple myeloma following early high dose therapy and autologous hematopoietic cell transplantation (SCT)

Gregory Peter Kaufman, Morie A. Gertz, Angela Dispenzieri, Martha Lacy, Francis Buadi, David Dingli, Suzanne R. Hayman, Prashant Kapoor, S. Vincent Rajkumar, Shaji Kumar (abstract; poster [PDF] courtesy of Dr. Kaufman)

8584 - A phase I/II trial of very low to low-dose continuous azacitidine in combination with standard doses of lenalidomide and low-dose dexamethasone in patients with relapsed or refractory multiple myeloma

Frederic J. Reu, Dale Grabowski, Reda Z. Mahfouz, Hillard M. Lazarus, Robert M. Dean, Beth Faiman, Janice Reed, Mary Ann Karam, Kimberly Hamilton, Sherry Fada, Matt E. Kalaycio, Jason Neil Valent, Christy Joy Samaras, Ronald M. Sobecks, Linda McCowen, Jamie Elberson, Hien Liu, Yogen Saunthararajah, Yap Chew, Mitchell R. Smith (abstract; poster [PDF] courtesy of Dr. Reu)

8585 - The therapeutic benefit and toxicity from multiple myeloma phase I trials, 2004 through 2014

Ehsan Malek, James J Driscoll, Jeffrey Welge (abstract)

8586 - Impact of total therapies on clinical outcome of myeloma stratified by risk and molecular subgroups

Christoph Johann Heuck, Niels Weinhold, Sharmilan Thanendrarajan, Caleb Konrad Stein, Frits Van Rhee, Adam Rosenthal, Yogesh Jethava, Rashid Khan, Antje Hoering, Faith E Davies, Bart Barlogie, Gareth John Morgan (abstract; poster [PDF] courtesy of Dr. Heuck)

8587 - Pre-clinical translational studies of daratumumab in patients with myeloma or AL amyloidosis undergoing autologous hematopoietic stem cell transplantation (SCT)

Chakra Pani Chaulagain, Xun Ma, Parul Doshi, Sandy Wai Kuan Wong, Andreas Kirschmer Klein, Kellie A. Sprague, Ping Zhou, Ray Comenzo (abstract; poster [PDF] courtesy of Dr. Chaulagain)

8588 - Effect of IMiD compounds on CD38 expression on multiple myeloma cells: MOR202, a human CD38 antibody in combination with pomalidomide

Rainer Boxhammer, Stefan Steidl, Jan Endell (abstract)

8589 - Patterns of AKT, mTOR, ERK, and STAT3 pathway activation in MGUS, smoldering multiple myeloma, and multiple myeloma

Jeremy Todd Larsen, Vijay Ramakrishnan, Linda Wellik, Teresa K. Kimlinger, S. Vincent Rajkumar, Shaji Kumar (abstract; poster [PDF] courtesy of Dr. Larsen)

8590 - Assessing clinical response in multiple myeloma (MM) patients treated with monoclonal antibodies (mAbs): Validation of a daratumumab IFE reflex assay (DIRA) to distinguish malignant M-protein from therapeutic antibody

Christopher McCudden, Amy Axel, Dominique Slaets, Sandy Frans, Jaime Bald, Jordan Mark Schecter, Tahamtan Ahmadi, Torben Plesner, Kate Sasser (abstract; poster [PDF] courtesy of Dr. McCudden)

8591 - Safety and efficacy of pomalidomide (POM), dexamethasone (DEX), and pegylated liposomal doxorubicin (PLD) for patients with relapsed/refractory multiple myeloma (RRMM)

James R. Berenson, Laura Stampleman, Alberto Bessudo, Peter Rosen, Leonard M. Klein, Thomas B. S. Woliver, Marshall S. Flam, Shahrooz Eshaghian, Youram Nassir, Regina A. Swift, Robert A. Vescio (abstract)

8592 - Clinical outcomes in t(11;14) multiple myeloma

Muhamad Alhaj Moustafa, S. Vincent Rajkumar, Angela Dispenzieri, Martha Lacy, Morie A. Gertz, Francis Buadi, David Dingli, Suzanne R. Hayman, Prashant Kapoor, Yi Lisa Hwa, John Anthony Lust, Ronald S. Go, Robert A. Kyle, Shaji Kumar (abstract; poster [PDF] courtesy of Dr. Alhaj Moustafa)

8593 - Analyzing the relationship of response and survival in patients with refractory or relapsed and refractory multiple myeloma (RRMM) treated with pomalidomide plus low-dose dexamethasone (POM + LoDEX) in the MM-003 trial

Katja Weisel, Philippe Moreau, Craig J Gibson, Kevin W. Song, Owain Saunders, Lars Axel Sternas, Kevin Hong, Mohamed H. Zaki, Meletios A. Dimopoulos (abstract; poster [PDF] courtesy of Dr. Weisel)